Atsushi Nohara1, Hirotoshi Ohmura2, Hiroaki Okazaki3, Masatsune Ogura4, Kazuo Kitagawa5, Masahiro Koseki6, Kayoko Sato7, Kazuhisa Tsukamoto8, Shizuya Yamashita9,10, On behalf of the Japan Atherosclerosis Society Working Group on Statement for Appropriate Use of PCSK9 Inhibitors
1Kanazawa University Health Service Center, 2Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 3Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, 4Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, 5Department of Neurology, Tokyo Women's Medical University, 6Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 7Department of Cardiology, Tokyo Women's Medical University, 8Department of Internal Medicine, Teikyo University School of Medicine, 9Department of Community Medicine & Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 10Rinku General Medical Center
Journal of Atherosclerosis and Thrombosis 25(8): 747-750, 2018.